



## **Synta to Participate in Three Investor Conferences in February**

February 16, 2012

*-Presenting at Citi Global and RBC Capital Markets Healthcare Conferences-*

*-Participating in UBS Small/Mid-Cap Conference-*

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 16, 2012-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the following upcoming investor conferences:

Citi 2012 Global Healthcare Conference in New York  
Monday, February 27 at 10:00 a.m. (ET)

RBC Capital Markets' 2012 Healthcare Conference in New York  
President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion titled:  
*Unique, Later Stage Cancer Treatment Opportunities*  
Tuesday, February 28 at 11:00 a.m. (ET)

A live audio webcast and replay of both the presentation and panel discussion will be available on the "Investors" section of the Company's website, [www.syntapharma.com](http://www.syntapharma.com).

Synta will also be attending the UBS Securities Small/Mid-Cap Conference in Boston, February 29, 2012. There is no formal presentation during the UBS Conference, however management will be available for one-on-one meetings during the conference.

### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

Source: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125